The role of p53 as a surrogate marker for chemotherapeutical responsiveness in ovarian cancer

Journal of Cancer Research and Clinical Oncology

Volumn 136, Issue 1, 2010, Pages 79-88

  Bauerschlag, Dirk O ^a   Schem, Christian ^b   Weigel, Marion T ^b   Von Kaisenberg, Constantin ^c   Strauss, Alexander ^b   Bauknecht, Thomas ^d   Maass, Nicolai ^a   Meinhold Heerlein, Ivo ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d LILLY DEUTSCHLAND GMBH   (Germany)

Author keywords

Chemotherapeutical responsiveness; Mutational analysis; Ovarian cancer; P53

Indexed keywords

MONOCLONAL ANTIBODY; MUTANT PROTEIN; PLATINUM; PROTEIN P53; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ANALYTIC METHOD; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DISEASE COURSE; DISEASE MARKER; FEMALE; FUNCTIONAL YEAST ASSAY; GENE SEQUENCE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MUTATION; MUTATIONAL ANALYSIS; OVARY CANCER; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROTEIN FUNCTION; SINGLE STRAND CONFORMATION POLYMORPHISM; TREATMENT RESPONSE; WILD TYPE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MUTATION; OVARIAN NEOPLASMS; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; SURGICAL PROCEDURES, OPERATIVE; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 71449108641     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-009-0639-8     Document Type: Article

References (57)

1. A Bali PM O'Brien, et al. 2004 Cyclin D1, p53, and p21Waf1/Cip1 expression is predictive of poor clinical outcome in serous epithelial ovarian cancer Clin Cancer Res 10 15 5168 5177 10.1158/1078-0432.CCR-03-0751 15297421 (Pubitemid 39099792)
2. F Bartel J Jung, et al. 2008 Both germ line and somatic genetics of the p53 pathway affect ovarian cancer incidence and survival Clin Cancer Res 14 1 89 96 10.1158/1078-0432.CCR-07-1192 18172257
3. G Bolis G Scarfone, et al. 2001 Carboplatin alone vs carboplatin plus epidoxorubicin as second-line therapy for cisplatin- or carboplatin-sensitive ovarian cancer Gynecol Oncol 81 1 3 9 10.1006/gyno.2001.6151 11277642 (Pubitemid 32368070)
4. B Budowle R Chakraborty, et al. 1991 Analysis of the VNTR locus D1S80 by the PCR followed by high-resolution PAGE Am J Hum Genet 48 1 137 144 1670750
5. JK Chan D Teoh, et al. 2008 Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers Gynecol Oncol 109 3 370 376 10.1016/j.ygyno.2008.02.006 18395777
6. DT Curiel DL Buchhagen, et al. 1990 A chemical mismatch cleavage method useful for the detection of point mutations in the p53 gene in lung cancer Am J Respir Cell Mol Biol 3 5 405 411 2223098
7. R Dehari RJ Kurman, et al. 2007 The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis Am J Surg Pathol 31 7 1007 1012 10.1097/PAS.0b013e31802cbbe9 17592266 (Pubitemid 47012296)
8. A du Bois HJ Luck, et al. 2003 A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer J Natl Cancer Inst 95 17 1320 1329 12953086
9. Z Feng W Hu, et al. 2007 Declining p53 function in the aging process: a possible mechanism for the increased tumor incidence in older populations Proc Natl Acad Sci USA 104 42 16633 16638 10.1073/pnas.0708043104 17921246 (Pubitemid 350211068)
10. JM Flaman T Frebourg, et al. 1995 A simple p53 functional assay for screening cell lines, blood, and tumors Proc Natl Acad Sci USA 92 9 3963 3967 10.1073/pnas.92.9.3963 7732013
11. A Gadducci C Cianci, et al. 2000 p53 status is neither a predictive nor a prognostic variable in patients with advanced ovarian cancer treated with a paclitaxel-based regimen Anticancer Res 20 6C 4793 4799 11205220
12. A Gadducci S Cosio, et al. 2002 Molecular mechanisms of apoptosis and chemosensitivity to platinum and paclitaxel in ovarian cancer: biological data and clinical implications Eur J Gynaecol Oncol 23 5 390 396 12440809
13. A Gadducci C Di Cristofano, et al. 2006 P53 gene status in patients with advanced serous epithelial ovarian cancer in relation to response to paclitaxel-plus platinum-based chemotherapy and long-term clinical outcome Anticancer Res 26 1B 687 693 16739339
14. V Galic J Willner, et al. 2007 Common polymorphisms in TP53 and MDM2 and the relationship to TP53 mutations and clinical outcomes in women with ovarian and peritoneal carcinomas Genes Chromosom Cancer 46 3 239 247 10.1002/gcc.20407 17171684 (Pubitemid 46155319)
15. UB Gyllensten HA Erlich 1988 Generation of single-stranded DNA by the polymerase chain reaction and its application to direct sequencing of the HLA-DQA locus Proc Natl Acad Sci USA 85 20 7652 7656 10.1073/pnas.85.20.7652 3174659 (Pubitemid 18256428)
16. JW Harper GR Adami, et al. 1993 The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases Cell 75 4 805 816 10.1016/0092-8674(93)90499-G 8242751 (Pubitemid 23346377)
17. AP Heintz AT Van Oosterom, et al. 1988 The treatment of advanced ovarian carcinoma (I): clinical variables associated with prognosis Gynecol Oncol 30 3 347 358 10.1016/0090-8258(88)90249-1 3134277 (Pubitemid 18179519)
18. M Hollstein D Sidransky, et al. 1991 p53 mutations in human cancers Science 253 5015 49 53 10.1126/science.1905840 1905840
19. M Hollstein K Rice, et al. 1994 Database of p53 gene somatic mutations in human tumors and cell lines Nucleic Acids Res 22 17 3551 3555 7937055
20. R Holmila K Husgafvel-Pursiainen 2006 Analysis of TP53 gene mutations in human lung cancer: comparison of capillary electrophoresis single strand conformation polymorphism assay with denaturing gradient gel electrophoresis and direct sequencing Cancer Detect Prev 30 1 1 6 10.1016/j.cdp.2005.10.004 16458448 (Pubitemid 43374496)
21. A Inga R Iannone, et al. 1997 Determining mutational fingerprints at the human p53 locus with a yeast functional assay: a new tool for molecular epidemiology Oncogene 14 11 1307 1313 10.1038/sj.onc.1200952 9178891
22. C Ishioka T Frebourg, et al. 1993 Screening patients for heterozygous p53 mutations using a functional assay in yeast Nat Genet 5 2 124 129 10.1038/ng1093-124 8252037 (Pubitemid 23293446)
23. A Jemal R Siegel, et al. 2008 Cancer statistics, 2008 CA Cancer J Clin 58 2 71 96 10.3322/CA.2007.0010 18287387
24. H Kashiwazaki H Tonoki, et al. 1997 High frequency of p53 mutations in human oral epithelial dysplasia and primary squamous cell carcinoma detected by yeast functional assay Oncogene 15 22 2667 2674 10.1038/sj.onc.1201438 9400993
25. J Kupryjanczyk E Kraszewska, et al. 2008 TP53 status and taxane-platinum versus platinum-based therapy in ovarian cancer patients: a non-randomized retrospective study BMC Cancer 8 27 10.1186/1471-2407-8-27 18230133
26. RJ Kurman IeM Shih 2008 Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications Int J Gynecol Pathol 27 2 151 160 18317228
27. C Lavarino S Pilotti, et al. 2000 p53 gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma J Clin Oncol 18 23 3936 3945 11099323
28. AJ Levine 1997 p53, the cellular gatekeeper for growth and division Cell 88 3 323 331 10.1016/S0092-8674(00)81871-1 9039259 (Pubitemid 27131374)
29. AJ Levine J Momand, et al. 1991 The p53 tumour suppressor gene Nature 351 6326 453 456 10.1038/351453a0 2046748
30. ME Lomax DM Barnes, et al. 1997 Two functional assays employed to detect an unusual mutation in the oligomerisation domain of p53 in a Li-Fraumeni like family Oncogene 14 15 1869 1874 10.1038/sj.onc.1201133 9150393
31. R Mazars P Pujol, et al. 1991 p53 mutations in ovarian cancer: a late event? Oncogene 6 9 1685 1690 1923532
32. I Meinhold-Heerlein E Ninci, et al. 2001 Evaluation of methods to detect p53 mutations in ovarian cancer Oncology 60 2 176 188 10.1159/000055316 11244334 (Pubitemid 32245337)
33. I Meinhold-Heerlein D Bauerschlag, et al. 2005 Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential Oncogene 24 6 1053 1065 10.1038/sj.onc.1208298 15558012 (Pubitemid 40313882)
34. I Meinhold-Heerlein D Bauerschlag, et al. 2007 An integrated clinical-genomics approach identifies a candidate multi-analyte blood test for serous ovarian carcinoma Clin Cancer Res 13 2 Pt 1 458 466 10.1158/1078-0432. CCR-06-0691 17255266 (Pubitemid 46225350)
35. SA Miller DD Dykes, et al. 1988 A simple salting out procedure for extracting DNA from human nucleated cells Nucleic Acids Res 16 3 1215 10.1093/nar/16.3.1215 3344216
36. K Nakayama Y Takebayashi, et al. 2003 Prognostic value of overexpression of p53 in human ovarian carcinoma patients receiving cisplatin Cancer Lett 192 2 227 235 10.1016/S0304-3835(02)00686-9 12668287 (Pubitemid 36369277)
37. JP Neijt SA Engelholm, et al. 2000 Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer J Clin Oncol 18 17 3084 3092 10963636
38. BV Offersen J Alsner, et al. 2008 A comparison among HER2, TP53, PAI-1, angiogenesis, and proliferation activity as prognostic variables in tumours from 408 patients diagnosed with early breast cancer Acta Oncol 47 4 618 632 10.1080/02841860801958295 18465330 (Pubitemid 351878436)
39. RF Ozols BN Bundy, et al. 2003 Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study J Clin Oncol 21 17 3194 3200 10.1200/JCO.2003.02.153 12860964 (Pubitemid 46606249)
40. J Pfisterer M Plante, et al. 2006 Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG J Clin Oncol 24 29 4699 4707 10.1200/JCO.2006.06.0913 16966687 (Pubitemid 46630933)
41. C Prives PA Hall 1999 The p53 pathway J Pathol 187 1 112 126 10.1002/(SICI)1096-9896(199901)187:1<112::AID-PATH250>3.0.CO;2-3 10341712 (Pubitemid 29009841)
42. A Psyrri P Kountourakis, et al. 2007 Analysis of p53 protein expression levels on ovarian cancer tissue microarray using automated quantitative analysis elucidates prognostic patient subsets Ann Oncol 18 4 709 715 10.1093/annonc/mdl479 17220511 (Pubitemid 46523275)
43. M Rentrop B Knapp, et al. 1986 Aminoalkylsilane-treated glass slides as support for in situ hybridization of keratin cDNAs to frozen tissue sections under varying fixation and pretreatment conditions Histochem J 18 5 271 276 10.1007/BF01676237 2427482
44. R Salani RJ Kurman, et al. 2008 Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance Int J Gynecol Cancer 18 3 487 491 10.1111/j.1525-1438.2007.01039.x 17692090 (Pubitemid 351668307)
45. F Sanger S Nicklen, et al. 1977 DNA sequencing with chain-terminating inhibitors Proc Natl Acad Sci USA 74 12 5463 5467 10.1073/pnas.74.12.5463 271968
46. M Schuijer EM Berns 2003 TP53 and ovarian cancer Hum Mutat 21 3 285 291 10.1002/humu.10181 12619114 (Pubitemid 36292970)
47. AN Shelling IE Cooke, et al. 1995 The genetic analysis of ovarian cancer Br J Cancer 72 3 521 527 7669555
48. IeM Shih RJ Kurman 2004 Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis Am J Pathol 164 5 1511 1518 15111296
49. G Singer RJ Kurman, et al. 2002 Diverse tumorigenic pathways in ovarian serous carcinoma Am J Pathol 160 4 1223 1228 11943707
50. G Singer IeM Shih, et al. 2003 Mutational analysis of K-ras segregates ovarian serous carcinomas into two types: invasive MPSC (low-grade tumor) and conventional serous carcinoma (high-grade tumor) Int J Gynecol Pathol 22 1 37 41 10.1097/00004347-200301000-00009 12496696 (Pubitemid 36014274)
51. G Singer R Stohr, et al. 2005 Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation Am J Surg Pathol 29 2 218 224 10.1097/01.pas.0000146025.91953.8d 15644779 (Pubitemid 40170640)
52. JS Skilling A Sood, et al. 1996 An abundance of p53 null mutations in ovarian carcinoma Oncogene 13 1 117 123 8700537
53. ML Smith IT Chen, et al. 1994 Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen Science 266 5189 1376 1380 10.1126/science.7973727 7973727
54. Y Ueno T Enomoto, et al. 2006 Prognostic significance of p53 mutation in suboptimally resected advanced ovarian carcinoma treated with the combination chemotherapy of paclitaxel and carboplatin Cancer Lett 241 2 289 300 10.1016/j.canlet.2005.10.035 16459017 (Pubitemid 44163043)
55. B Vogelstein D Lane, et al. 2000 Surfing the p53 network Nature 408 6810 307 310 10.1038/35042675 11099028
56. F Waridel A Estreicher, et al. 1997 Field cancerisation and polyclonal p53 mutation in the upper aero-digestive tract Oncogene 14 2 163 169 10.1038/sj.onc.1200812 9010218
57. WH Wen A Reles, et al. 1999 p53 mutations and expression in ovarian cancers: correlation with overall survival Int J Gynecol Pathol 18 1 29 41 9891239